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This study was designed to evaluate the efficacy and tolerability of a weekly schedule of epirubicin in combination with docetaxel in
the first-line treatment of patients with metastatic breast cancer (MBC). A total of 43 women with MBC not previously treated with
chemotherapy for metastatic disease received weekly epirubicin 25mgm
 2 and docetaxel 25mgm
 2 for a maximum of five cycles
(total cumulative epirubicin dose of p900mgm
 2). Dose reduction was not permitted. Objective response and evaluation of
toxicity profile were the primary study end points; time to progression and overall survival were secondary end points. Patients were
followed for a median of 21 (4–38) months. Analysis was by intent to treat; 33 patients completed five cycles of therapy, and
the median dose of epirubicin administered to the 43 patients was 23mgm
 2. Twenty-five patients (58%) achieved a partial
response and one (2%) achieved a complete response. An additional 12 patients (28%) had stable disease. The median time to
progression was 11 months (95% confidence intervals (CI) 7–14) overall, and 13 months (95% CI 12–14) in the 26 patients who
responded to treatment. Median overall survival was 25 months for responders and 14 months for nonresponders. Grade 3/4
neutropenia occurred in 16% of patients and in 6% of cycles. One patient developed cardiac toxicity (20% reduction in left ventricular
ejection fraction). The combination of epirubicin plus docetaxel is highly active in MBC, with a manageable toxicity profile. Such a
weekly schedule might provide a valuable treatment option for MBC.
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Breast cancer is the most prevalent malignancy globally and the
leading cause of cancer-related death in women, with more than a
million newly diagnosed cases occurring worldwide annually
(Parkin et al, 2005). Furthermore, it is estimated that 30–75% of
patients undergoing surgery and adjuvant treatment will develop
recurrent disease (Paridaens, 2000).
Metastatic breast cancer (MBC) is essentially incurable with
standard therapy and patients with MBC have a median survival of
about 2 years after metastases have been detected (Henderson,
1991). As a consequence, treatment goals are to improve
symptoms, prolong survival, and maintain or improve quality of
life. A 5-year survival rate ranging from 10 to 30% has been
observed in metastatic disease confined to the bone, which is
characterised by an indolent clinical course. However, patients
with visceral (mainly liver) metastases have a worse prognosis and
a median survival time of approximately 8 months (Piccart, 1996).
Thus, treatment end points of MBC are currently improvement of
objective response rate (ORR), time to progression (TTP) and
overall survival (OS), but the role of chemotherapy in this setting is
still unclear.
The taxanes and the anthracyclines are considered among the
most active single agents for the first-line treatment of MBC.
Consequently, the combined use of taxanes and anthracyclines is a
logical step in the search for highly effective chemotherapy
combinations. Unfortunately, the clinical utility of anthracyclines
is limited by cardiac toxicity. Epirubicin, however, is less
cardiotoxic than doxorubicin, showing a toxicity ratio of 1:1.8
when compared to the latter, while retaining similar activity and
efficacy (Robert, 1993). Furthermore, the semisynthetic taxane
docetaxel retains much of its therapeutic activity even in patients
unresponsive to anthracyclines (Ten Bokkel-Huinink et al, 1994;
Ravdin et al, 1995; Valero et al, 1995). In addition to the high
clinical activity of the two drug classes and the lack of complete
clinical cross-resistance, docetaxel and epirubicin have largely
non-overlapping toxicity profiles and different mechanisms of
action (topoisomerase II inhibition vs microtubular assembly
disturbance). Combination chemotherapy with a 3-week schedule
in phase II trials improved response (46–88%) (Mavroudis et al,
2000; Pagani et al, 2000; Milla-Santos et al, 2001; Morales et al,
2004) without an associated higher incidence of cardiotoxicity.
The high response rates were attained in patients with un-
favourable prognostic factors, including multiple metastatic sites,
visceral metastases and prior exposure to adjuvant chemotherapy.
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sHowever, the dose-limiting toxicity for this combination was
neutropenia.
A dose–response relationship has been shown for single agent
epirubicin in women with MBC (Bastholt et al, 1996). Doubling the
epirubicin dose from 50 to 100mgm
 2 also was shown to
significantly increase ORR values in a phase III study in MBC
(Brufman et al, 1997).
A strategy to reduce toxicity without prophylactic granulocyte
colony-stimulating factor (G-CSF) support is to use the combina-
tion therapy according to a weekly schedule. A weekly schedule
could maintain peak blood concentrations below the threshold
value of medullar toxicity. This results in a more favourable safety
profile, and facilitates maintenance of the correct dosing schedule
and completion of the administration cycles (Norton, 1988, 2005;
Burstein et al, 2000; Stammler et al, 2001; Wenzel et al, 2002).
On the basis of these premises, the present study was designed
to evaluate the therapeutic efficacy and tolerability of a regimen of
weekly epirubicin in combination with docetaxel in the first-line
treatment of MBC.
PATIENTS AND METHODS
Patient eligibility
The study included women, aged more than 18 years, with a
histological or cytological diagnosis of MBC and who had not
received previous chemotherapy for metastatic disease. Geo-
graphic accessibility for the treatment and follow-up was
considered as an inclusion criterion. Previous adjuvant and/or
neoadjuvant chemotherapy were allowed provided that they had
been completed at least 1 year before enrolment. If patients
received anthracyclines as adjuvant treatment, disease progression
had to have occurred at least 12 months after completion of
anthracycline treatment. The cumulative previous anthracycline
dose was not to exceed 240mgm
 2 for doxorubicin or 450mgm
 2
for epirubicin. Previous hormone adjuvant therapy or treatment
for metastatic disease was allowed. Other inclusion criteria were
the presence of at least one lesion measurable in two dimensions,
World Health Organization performance status 0–2, adequate
haematological function (neutrophils X1500 10
9l
 1, haemo-
globin X10gdl
 1 and platelets X100 10
9l), creatinine
p140mmoll
 1 (1.6mgdl
 1), bilirubin p1.5-fold the upper
normal limit, aspartate and alanine aminotransferase p1.5 times
the upper normal limit, alkaline phosphatase p2.5-fold the upper
normal limit (with the exception of bone metastases in the absence
of liver metastases), absence of congestive heart failure or angina
even if therapeutically controlled, absence of arterial hypertension
or arrhythmias not under pharmacological control, absence of
myocardial infarction or unstable angina pectoris in the 12 months
before the onset of the study, and normal cardiac function
evaluated by 12-lead electrocardiogram and echocardiography
(normal left ventricular ejection fraction (LVEF X50%)).
Patients were excluded if they had received radiation therapy of
the lesion chosen to evaluate response to treatment, with the
exception of progressive disease. Radiation therapy must have
been completed at least 4 weeks before the study. Bone marrow
irradiation of an area equal to 20% was allowed. Patients with
symptomatic brain or leptomeningeal metastases, infection,
malnutrition or a history of secondary malignant neoplasm other
than basal or squamous cell carcinoma of the skin, or carcinoma
in situ of the uterine neck (adequately treated and not relapsing in
the 5 years preceding the study) were not included. Additional
exclusion criteria were previous history of neurological or
psychiatric diseases, symptomatic peripheral neuropathy above
grade 2, severe respiratory failure, uncontrolled diabetes mellitus,
acute peptic ulcer or other contraindication to the use of
corticosteroid premedication, concomitant treatment with other
experimental drugs, concomitant hormone therapy, pregnancy and
breastfeeding. The Ethics and Scientific Institutional Review
Boards of the participating centres approved the study. All patients
signed an informed consent form before entering the study.
Patient evaluation
Baseline evaluation not exceeding 4 weeks before the first infusion
consisted of a complete medical history and physical examination.
Serum biochemical profile, electrocardiogram, chest radiograph,
abdominal ultrasound and/or computed tomography scan, mea-
surement of carcinoembryonic antigen and CA 15.3 determination,
bone scintigraphy and bone X-ray were all performed at the time
of enrolment. Appropriate imaging studies to assess objective
response (chest X-ray, abdomen ultrasound, CT scan of thorax and
abdomen, bone scintigraphy or X-ray) were performed after the
1st, 3rd and 5th cycle of treatment.
Study design
Patients were treated weekly with epirubicin (Farmorubicine;
Pharmacia, Milan, Italy) 25mgm
 2 administered as a 15-min
intravenous infusion followed 1h later by docetaxel (Taxotere;
Aventis, Antony, France) 25mgm
 2 as a 60-min intravenous
infusion, according to a schedule of 6 weeks in every 8 for the first
cycle then 3 weeks in every 5. Treatment continuation after the
first cycle was allowed in the presence of an objective response or
stable disease and in the absence of severe toxicity. All patients
were given prophylactic corticosteroid premedication to avoid
hypersensitivity reactions and to prevent the occurrence of uid
retention; this consisted of oral prednisone 25mg 12h before and
24h after treatment, dexamethasone 4mg and ranitidine 50mg
30min before infusion; prophylactic antiemetic treatment con-
sisted of 5-hydroxytryptamine type-3 receptor antagonists admi-
nistered 30min before infusion and when needed. A maximum of
five cycles were given for a total cumulative epirubicin dose of
p900mgm
 2 during the study period. No dose reduction was
permitted. Treatment was delayed for 1–2 weeks in the event of
febrile neutropenia, thrombocytopenia Xgrade 2, gastrointestinal
toxicity Xgrade 2 and neurological toxicity Xgrade 2. Epirubicin
administration was delayed in patients who developed LVEF
p10% of the initial value or below the normal limit.
Assessment of toxicity
Weekly blood cell count, monthly complete serum biochemistry,
electrocardiogram every two cycles, and echocardiography after
the 1st and 3rd cycle and at the end of treatment to evaluate LVEF
were performed. Toxic effects were graded by the National Cancer
Institute Common Toxicity Criteria. Physical evaluation and
performance status scoring were also performed at the same time
points. An undesired event, whether or not related to the
administered drugs, was defined as an adverse reaction. This
included any side effect, trauma, toxicity or hypersensitivity
reaction, as well as any unexpected clinical or laboratory result. A
fatal event, or any event causing life-threatening injury, requiring
hospitalisation or producing disability was considered a serious
adverse event. Death or congenital anomalies not related to
primary disease or drug overdose were always considered as
serious events. Worsening of concomitant or predisposing disease
was considered as a serious event not related to the trial treatment,
or related to treatment failure or early effect.
Assessment of response
Assessment of antitumour activity was evaluated by the same
instrumental approach used to evaluate target lesion(s) at study
entry and was scored according to the Response Evaluation
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sCriteria in Solid Tumors (RECIST) Group criteria. Tumour
response was based on subsequent assessments performed after
the 1st and 3rd cycle and at the end of treatment. Objective
responses were graded according to standard criteria for complete
or partial response, stable disease, or no change, and progressive
disease. The TTP was calculated from the time of the first dose to
the time of the first objective evidence of tumour progression.
Overall survival was calculated from the time of patient enrolment
to the time of documented death. All patients who completed at
least the first cycle of therapy were considered eligible for response
to treatment evaluation.
Statistical analysis
The study was designed as a phase II trial. The primary objectives
were the evaluation of the therapeutic efficacy (response rate) of
combined epirubicin plus docetaxel as a first-line treatment for
patients with MBC and the evaluation of the toxicity profile of this
combined regimen. Secondary objectives were the evaluation of
TTP and OS. All patients included in the trial were evaluated
according to intent-to-treat analysis. The sample size necessary for
the study was determined using the tables for single-stage phase II
trials based on the exact binomial distribution proposed by A’Hern
(2001). Considering a response rate of 40% as not acceptable and
seeking to evaluate whether treatment would lead to a response
rate of 60%, the calculated sample size was 42 patients with a
statistical power of 80% using the 5% level of significance. Unless
otherwise specified, results are reported as median (range) along
with 95% confidence intervals (CI). The Kaplan–Meier method
was used to calculate OS and progression-free survival curves, and
the significance test was assessed according to the Mantel log-rank
test. All calculations were made using computer software packages
SPSS 13.0.
RESULTS
Patient characteristics
Forty-three patients (median age 59 years, ranging from 36 to 79
years) were enrolled in the study and followed for a median of 21
months (range 4–38). Among the 43 patients, 42 (98%) had a
performance status of 0–1, 20 (46.5%) had one site of metastasis
and 5 (11.6%) had metastatic involvement of three or more sites.
Twenty-four patients (55.8%) had received previous adjuvant
chemotherapy, 14 (32.5%) with anthracyclines and 10 (23.3%) with
CMF. The baseline characteristics of the patients are listed in
Table 1.
Treatment
Of the 43 patients included in the study, 33 completed five cycles of
treatment, whereas 10 were withdrawn due to progressive disease
(six patients), adverse events (three patients: two chemotherapy-
related and one after a fracture of the femur) or refusal to continue
after the first cycle of treatment (one patient). Of the 190 treatment
cycles administered (median five cycles per patient, range 1–5),
two patients (4.7%) were delayed due to treatment toxicity and
eight patients (18.6%) were delayed due to non-drug-related
causes. The median duration of treatment delay was 159 days
(range 28–203 days). The median dose of epirubicin administered
to the 43 patients included in the analysis was 23 (range 17–25)
mgm
 2.
Adverse events
Toxicities per cycle and per patient are shown in Table 2. When all
cycles were considered, grade 3/4 neutropenia occurred in 7
patients (16%) and 11 cycles (6%). Grade 1/2 anaemia occurred in
Table 1 Baseline patient characteristics
Characteristic No. %
Total 43 100
Grading
G1 4 9.3
G2 13 30.2
G3 15 34.9
Unknown 11 25.6
Receptor status
ER  12 27.9
ER+ 28 65.1
ER Unknown 3 7.0
PR  14 32.6
PR+ 26 60.5
PR unknown 3 7.0
Her-2/neu  17 39.5
Her-2/neu+ 6 14.0
Her-2/neu unknown 20 46.5
Menopausal status
Pre 16 37.2
Post 27 62.8
Histotype
Ductal 37 86.0
Lobular 3 7.0
Other 3 7.0
Tumour size
T1 8 18.6
T2 18 41.9
T3 3 7.0
T4 7 16.3
Unknown 7 16.3
Nodal status
N0 11 25.6
N1 18 41.9
N2 6 14.0
N3 1 2.3
Unknown 7 16.3
Performance status
0 35 81.4
1 7 16.3
2 1 2.3
Previous adjuvant therapy
Chemotherapy
No 19 44.2
Anthracyclines 14 32.5
CMF 10 23.3
Radiation therapy
No 26 60.5
Yes 17 39.5
Hormone therapy
No 19 44.2
Yes 24 55.8
Hormone therapy for metastatic disease
No 34 79.1
Yes 9 20.9
Number of metastatic sites
1 20 46.5
2 18 41.9
3 5 11.6
Site of metastases
Soft tissues 7 16.3
Visceral 28 65.1
Bone 8 18.6
Abbreviations: CMF, cyclophosphamide plus methotrexate plus fluorouracil; ER,
estrogen receptor; PR, progesterone receptor.
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most frequent non-haematological toxicities were seen in four
patients (9%) who had grade 3 asthenia and two patients (5%) who
developed grade 3 gastrointestinal events (diarrhea in one patient
and vomiting in the other). Mild fluid retention or oedema was
observed in five patients (12%). The median LVEF was 60% (range
51–79%) at baseline and 62% (range 48–78%) at the end of
treatment. One patient had asymptomatic cardiac toxicity (20%
reduction in LVEF; from 60 to 48%).
Efficacy
Twenty-five of the 43 patients enrolled in the study (58.1%)
achieved a partial response, and 1 (2.3%) had a complete response,
for an ORR of 61% (95% CI 46–75; Table 3). Stable disease was
seen in 12 patients (27.9%) and progressive disease in 5 (11.6%)
during or after completion of treatment. The ORRs were not
influenced by the previous adjuvant treatment. In fact no
statistically significant differences were observed in the responses’
distribution in patients who had not received adjuvant chemo-
therapy, CMF or anthracyclines (RR, respectively, 63.2 vs 70 vs
50%; P¼0.58).
With a median follow-up of 21 months, the median TTP was 11
months (95% CI 7–14) and OS 28 months (95% CI 21–36). In 26
patients who responded to treatment, the TTP was 13 months (95%
CI 12–14) compared to 7 months (95% CI 2–11) in 17 patients
who did not respond. Median OS was 29 months (95% CI 22–35)
for responsive patients compared to 20 months (95% CI 16–26) in
patients who did not respond to treatment. Progression-free
survival and OS over time are presented in Figure 1A and B,
respectively.
DISCUSSION
The combination of anthracyclines and docetaxel has demon-
strated significant activity as first-line chemotherapy in MBC. The
rationale for combining docetaxel with anthracyclines rests on a
number of observations. Individually they have the greatest single-
agent activity in patients with advanced breast cancer, lack
substantial clinical cross-resistance and have largely non-over-
lapping patterns of commonly encountered adverse events
(Nabholtz, 2003). In particular, increased cardiac toxicity has not
been reported in clinical trials. The dose-limiting toxicity for this
combination is myelosuppression, specifically a high incidence of
grade 4 neutropenia and febrile neutropenia, which is manageable
with haematopoietic growth factors (Morales et al, 2004). A clear
dose–response relationship has been demonstrated for epirubicin
and docetaxel as single agents, with or without G-CSF support
(Bastholt et al, 1996; Trudeau et al, 1996; Sparano et al, 2000;
Milla-Santos et al, 2001). However, it was recently reported that
dose-escalated epirubicin and docetaxel every 3 weeks, with
prophylactic G-CSF, resulted in severe myelosuppression without
improving efficacy, compared with other studies of taxane/
anthracycline combinations (Fabi et al, 2004). Hence, the current
study was aimed at evaluating the therapeutic efficacy and
tolerability of epirubicin plus docetaxel combination regimen
administered on a weekly schedule.
Table 2 Adverse events per patient and per cycle
Patients (%) Cycles (%)
Grade Grade
Adverse event 1 2 3 4 1 2 3 4
Asthenia 23.3 11.6 9.3 0 14.2 3.7 2.1 0
Cardiac 0 2.3 0 0 0 0.5 0 0
Cutaneous 2.3 0 2.3 0 0.5 0 0.5 0
Diarrhea 9.3 7.0 2.3 0 3.2 2.6 0.5 0
Anemia 20.9 11.6 0 0 13.2 4.2 0 0
Hypersensitivity 0 0 0 0 0 0 0 0
Leucopenia 2.3 4.7 0 0 0.5 1.1 0 0
Stomatitis 9.3 11.6 2.3 0 3.2 3.2 0.5 0
Nausea 23.3 4.7 0 0 8.4 1.1 0 0
Neurological 4.7 0 0 0 2.1 0 0 0
Neutropenia 14.0 9.3 11.6 4.7 7.4 5.8 4.2 1.6
Thrombocytopenia 9.3 0 0 2.3 4.2 0 0 0.5
Fluid retention 7.0 4.7 0 0 3.2 2.1 0 0
Vomiting 14.0 4.7 2.3 0 6.3 2.1 0.5 0
Table 3 OS and progression-free survival for patients treated with
weekly epirubicin in combination with docetaxel
Survival (%)
1-year 74.4
2-year 59.1
3-year 40.6
Median overall survival, months (95% CI) 28 (21–36)
Progression-free survival (%)
1-year 46.5
2-year 11.6
Median time to progression, months (95% CI) 11 (7–14)
Abbreviations: CI, confidence intervals; OS, overall survival.
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Figure 1 (A) Progression-free survival of patients treated with weekly
epirubicin in combination with docetaxel. (B) Overall survival of patients
treated with weekly epirubicin in combination with docetaxel.
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sThe rational behind this choice was centred on the dose-density
theory based on the reduction of the intervals between chemo-
therapy doses to restrict the opportunity for cancer cells to
become resistant to drugs and to target cell clones with differing
growth rates. Furthermore, weekly administration of chemo-
therapy in a dose-dense schedule is understood to have an
anti-angiogenesis effect, constricting the blood supply to tumours
and restricting their growth. Thus, the weekly schedule was
designed to allow administration of a total dose of drug greater
than or equal to that administered with the conventional 3-week
schedule, to enhance cumulative cytotoxic activity while reducing
the toxicity of the treatment, providing greater therapeutic
benefit together with a more favourable tolerability profile
(Norton, 1988, 2005; Burstein et al, 2000; Stammler et al, 2001;
Wenzel et al, 2002).
The ORR achieved with this schedule (60.5% (95% CI 45.9–
75.1)) was similar in patients with or without previous chemother-
apy, and with or without previous anthracycline exposure.
Complete and partial response rates were 2.3 and 58.1%,
respectively. The median TTP in patients who responded was 13
months (95% CI 12–14) and the median OS was 29 months (95%
CI 22–35). Our findings are similar to those reported for the
docetaxel arm in a phase III trial in which doxorubicin
(50mgm
 2) and docetaxel (75mgm
 2) was compared with
doxorubicin (60mgm
 2) and cyclophosphamide (600mgm
 2)
for a maximum of eight cycles in 423 patients with MBC (Nabholtz
and Riva, 2001). Patients included in the docetaxel arm showed a
significantly improved ORR (60%, P¼0.012) and median TTP
(37.1 weeks, P¼0.0153). In the phase II study performed by
Mavroudis et al (2000), treatment with 70mgm
 2 of epirubicin
and 90mgm
 2 of docetaxel resulted in an ORR of 66% with a
median TTP of 11 months. The combination of docetaxel and
epirubicin without G-CSF support resulted in febrile neutropenia
in approximately 15% of cycles in a trial by Pagani et al (1999) and
in 4 and 7% of cycles in the trials by Morales et al (2004) and
Mavroudis et al (2000), respectively. In our study, febrile
neutropenia was not observed.
Although the number of patients enrolled was small, this result
is very promising, particularly considering that prophylactic G-
CSF was not given, and that G-CSF support for the treatment of
grade 3/4 neutropenia was given in only 5.8% of cycles.
Importantly, cardiac toxicity, as evidenced by reduced LVEF, was
observed in only one patient.
The median duration of response (10 months), TTP (11 months)
and OS (28 months) in our trial are very acceptable for patients
with an incidence of visceral metastases of approximately 65% and
a high rate of adjuvant chemotherapy, including anthracyclines.
Furthermore, the results are very similar to those found in other
studies using a conventional 3-week schedule.
In conclusion, our study confirmed that the combination of
docetaxel and epirubicin is highly active in MBC and has a
favourable toxicity profile when administered in a weekly
schedule, which allowed administration of the full-programmed
dosages without the necessity of dosage reduction due to side
effects. This is of particular importance to allow the administration
of effective regimens providing clinical benefit to an often-elderly
population of patients with metastatic disease. The lack of cardiac
toxicity of this regimen is also of particular interest because anti-
HER 2 therapies, now widely available, may increase the risk of
cardiac morbidity in patients heavily pretreated with anthracy-
clines. Furthermore, compared to standard monochemotherapy
treatments with Docetaxel every 3 weeks, this regimen shows to be
more effective and less toxic (O’Shaughnessy et al, 2002). The
combination of epirubicin and docetaxel in a weekly schedule
might be considered as an important option in the treatment
of MBC.
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